GSK新任CEO Luke Miels在接替Emma Walmsley后,首次明确了他的管理风格:更激进的外部并购、更严苛的管线审查,以及向“以产品为中心”的转型。并购策略:寻找“隐藏在众目睽睽”的机会Miels 明确了GSK未来的交易逻辑,重点不再是单纯的大规模收购,而是精准的“补强型”收购(Bolt-on deals),理想的交易范围在20亿-40亿美元之间。筛选标准为那些定价合理、不一定属于...
Source LinkGSK新任CEO Luke Miels在接替Emma Walmsley后,首次明确了他的管理风格:更激进的外部并购、更严苛的管线审查,以及向“以产品为中心”的转型。并购策略:寻找“隐藏在众目睽睽”的机会Miels 明确了GSK未来的交易逻辑,重点不再是单纯的大规模收购,而是精准的“补强型”收购(Bolt-on deals),理想的交易范围在20亿-40亿美元之间。筛选标准为那些定价合理、不一定属于...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.